Discovery Life Sciences

Discovery integrates both. Its Biomarker Services division generates multi-omics data — including next-generation sequencing, spatial transcriptomics, multiplex immunohistochemistry, and proteomics — from its biobanked and client-provided specimens. This dual model separates the firm from pure-specimen brokers, enabling a single-provider workflow from tissue acquisition through assay-ready datasets.

Financial terms of the 2022 Astorg acquisition were not publicly disclosed, and the company does not publish revenue or deployment figures. As a privately held, sponsor-backed entity, it is valued on its laboratory capacity, specimen inventory scale, and contractual pharma partnerships rather than a publicly reported asset base.

While the firm's primary client base includes 8 of the top 10 global pharmaceutical companies, its procurement network and laboratory services are also available to academic medical centers, government research programs, and clinical cooperative groups through standard master services agreements.

The company executed over a dozen acquisitions from 2018 onward, absorbing firms including Conversant Bio, the HudsonAlpha Institute for Biotechnology's clinical sequencing laboratory, and QualTek Molecular Laboratories. This inorganic expansion built its dual physical presence in Huntsville and Pennsylvania, added European lab capacity, and consolidated a fragmented biospecimen broker market under one operational umbrella.